Tildrakizumab is an interleukin-23 antagonist used to treat moderate to severe plaque psoriasis. Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis.
- Mechanism
- Curator reviewed · 2 references
This drug selectively binds interleukin (IL)-23 p19 subunit of cytokine IL-23 and neutralizes its function IL-23 regulates Th17 cells and is a powerful activator of keratinocyte proliferation. Targeting IL-23p19 alone has been found to be a promising treatment approach in patients with moderate-to-severe chronic plaque psoriasis. Upon administration, downregulation of Th17 and Th22 cell responses occur.
IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.
- Primary indication
- Moderate-severe plaque psoriasis.Curator reviewed · 1 structured indication
- Formula / weight
- C6426H9918N1698O2000S46 · 144400.0 Da
- First approval
- Canada, 2022 · United States, 2018 · European Union, 2020
- Also known as
- tildrakizumab-asmn
- Code names
- MK-3222 · SCH 900222
- Brand names
Resolves to
What you can answer from here — as of August 03, 2026
Which drugs share a target with Tildrakizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account